- Home
- CNTA
as 12-20-2024 4:00pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 2.3B | IPO Year: | 2021 |
| Target Price: | $23.71 | AVG Volume (30 days): | 705.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.65 - $18.97 | Next Earning Date: | 11-12-2024 |
| Revenue: | $6,853,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HUSSAIN IQBAL J | CNTA | General Counsel | Dec 16 '24 | Sell | $16.39 | 77,705 | $1,273,755.90 | 125,785 | |
| Bush Tia L | CNTA | Chief Technology & Quality Ofc | Dec 16 '24 | Sell | $17.18 | 27,424 | $477,890.14 | 147,615 | |
| Anderson Karen M. | CNTA | Chief People Officer | Dec 13 '24 | Sell | $17.17 | 16,500 | $284,010.04 | 71,525 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Dec 6 '24 | Sell | $18.46 | 87,496 | $1,615,254.91 | 575,661 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Nov 25 '24 | Sell | $17.66 | 10,000 | $176,601.00 | 183,266 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Nov 25 '24 | Sell | $18.23 | 299 | $5,450.77 | 575,661 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Nov 20 '24 | Sell | $17.79 | 60,182 | $1,023,225.72 | 575,661 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Nov 13 '24 | Sell | $18.28 | 32,023 | $585,418.87 | 575,661 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Oct 25 '24 | Sell | $15.38 | 11,742 | $180,628.36 | 183,266 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Oct 21 '24 | Sell | $15.59 | 55,000 | $863,727.20 | 575,661 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Centessa Pharmaceuticals Insider Sold Shares Worth $959,057, According to a Recent SEC Filing
Insider Monkey
2 days ago
Why Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?
MT Newswires
5 days ago
Centessa Pharmaceuticals Insider Sold Shares Worth $284,010, According to a Recent SEC Filing
MT Newswires
16 days ago
Centessa Pharmaceuticals Insider Sold Shares Worth $1,615,255, According to a Recent SEC Filing
MT Newswires
a month ago
Morgan Stanley Lifts Price Target on Centessa Pharmaceuticals to $27 From $26, Keeps Overweight Rating
BioPharma Dive
a month ago
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
MT Newswires
a month ago
Centessa Pharmaceuticals' Q3 Loss Widens
GlobeNewswire
a month ago
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.